Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Login

    ARS Pharmaceuticals Inc.

    NASDAQ: SPRY · Real-Time Price · USD
    15.13
    -0.26 (-1.69%)
    At close: Jun 16, 2025, 12:51 PM

    ARS Pharmaceuticals Statistics

    Share Statistics

    ARS Pharmaceuticals has 98.21M shares outstanding. The number of shares has increased by 1.26% in one year.

    Shares Outstanding

    n/a
    		 98.21M

    Shares Change (YoY)

    n/a
    		 1.26%

    Shares Change (QoQ)

    n/a
    		 0.96%

    Owned by Institutions (%)

    n/a
    		 73.49%

    Shares Floating

    n/a
    		 54.77M

    Failed to Deliver (FTD) Shares

    n/a
    		 2,784

    FTD / Avg. Volume

    n/a
    		 0.17%

    Short Selling Information

    The latest short interest is 17.14M, so 17.45% of the outstanding shares have been sold short.

    Short Interest

    n/a
    		 17.14M

    Short % of Shares Out

    n/a
    		 17.45%

    Short % of Float

    n/a
    		 28.54%

    Short Ratio (days to cover)

    n/a
    		 11.38

    Valuation Ratios

    The PE ratio is 127.87 and the forward PE ratio is -20.29. ARS Pharmaceuticals's PEG ratio is -1.12.

    PE Ratio

    n/a
    		 127.87

    Forward PE

    n/a
    		 -20.29

    PS Ratio

    n/a
    		 11.47

    Forward PS

    n/a
    		 2.2

    PB Ratio

    n/a
    		 3.98

    P/FCF Ratio

    n/a
    		 78.76

    PEG Ratio

    n/a
    		 -1.12
    Financial Ratio History

    Enterprise Valuation

    ARS Pharmaceuticals has an Enterprise Value (EV) of 971.91M.

    EV / Sales

    n/a
    		 10.9

    EV / EBITDA

    n/a
    		 -315.25

    EV / EBIT

    n/a
    		 71.74

    EV / FCF

    n/a
    		 74.85

    Financial Position

    The company has a current ratio of 14.26, with a Debt / Equity ratio of 0.

    Current Ratio

    n/a
    		 14.26

    Quick Ratio

    n/a
    		 14.04

    Debt / Equity

    n/a
    		 0

    Debt / EBITDA

    n/a
    		 -0.01

    Debt / FCF

    n/a
    		 n/a

    Interest Coverage

    n/a
    		 0

    Financial Efficiency

    Return on Equity is 3.11% and Return on Invested Capital is -0.91%.

    Return on Equity

    n/a
    		 3.11%

    Return on Assets

    n/a
    		 2.28%

    Return on Invested Capital

    n/a
    		 -0.91%

    Revenue Per Employee

    n/a
    		 $575,154.84

    Profits Per Employee

    n/a
    		 $51,600

    Employee Count

    n/a
    		 155

    Asset Turnover

    n/a
    		 0.25

    Inventory Turnover

    n/a
    		 0.19

    Taxes

    Income Tax

    n/a
    		 288K

    Effective Tax Rate

    n/a
    		 3.48%

    Stock Price Statistics

    The stock price has increased by 78.06% in the last 52 weeks. The beta is 0.87, so ARS Pharmaceuticals's price volatility has been higher than the market average.

    Beta

    n/a
    		 0.87

    52-Week Price Change

    n/a
    		 78.06%

    50-Day Moving Average

    n/a
    		 14.06

    200-Day Moving Average

    n/a
    		 13.32

    Relative Strength Index (RSI)

    n/a
    		 60.21

    Average Volume (20 Days)

    n/a
    		 1,668,504

    Income Statement

    In the last 12 months, ARS Pharmaceuticals had revenue of 89.15M and earned 8M in profits. Earnings per share was 0.08.

    Revenue

    n/a
    		 89.15M

    Gross Profit

    n/a
    		 88.17M

    Operating Income

    n/a
    		 -3.08M

    Net Income

    n/a
    		 8M

    EBITDA

    n/a
    		 -2.88M

    EBIT

    n/a
    		 -3.08M

    Earnings Per Share (EPS)

    n/a
    		 0.08
    Full Income Statement

    Balance Sheet

    The company has 50.82M in cash and 42K in debt, giving a net cash position of 50.77M.

    Cash & Cash Equivalents

    n/a
    		 50.82M

    Total Debt

    n/a
    		 42K

    Net Cash

    n/a
    		 50.77M

    Retained Earnings

    n/a
    		 -123.31M

    Total Assets

    n/a
    		 327.32M

    Working Capital

    n/a
    		 276.24M
    Full Balance Sheet

    Cash Flow

    In the last 12 months, operating cash flow was 13.55M and capital expenditures -563K, giving a free cash flow of 12.98M.

    Operating Cash Flow

    n/a
    		 13.55M

    Capital Expenditures

    n/a
    		 -563K

    Free Cash Flow

    n/a
    		 12.98M

    FCF Per Share

    n/a
    		 0.13
    Full Cash Flow Statement

    Margins

    Gross margin is 98.9%, with operating and profit margins of -3.46% and 8.97%.

    Gross Margin

    n/a
    		 98.9%

    Operating Margin

    n/a
    		 -3.46%

    Pretax Margin

    n/a
    		 9.29%

    Profit Margin

    n/a
    		 8.97%

    EBITDA Margin

    n/a
    		 -3.46%

    EBIT Margin

    n/a
    		 -3.46%

    FCF Margin

    n/a
    		 14.57%

    Dividends & Yields

    SPRY does not appear to pay any dividends at this time.

    Dividend Per Share

    n/a
    		 n/a

    Dividend Yield

    n/a
    		 n/a

    Dividend Growth (YoY)

    n/a
    		 n/a

    Payout Ratio

    n/a
    		 n/a

    Earnings Yield

    n/a
    		 0.78%

    FCF Yield

    n/a
    		 1.27%
    Dividend Details

    Analyst Forecast

    The average price target for SPRY is $29, which is 88.1% higher than the current price. The consensus rating is "Buy".

    Price Target

    n/a
    		 $29

    Price Target Difference

    n/a
    		 88.1%

    Analyst Consensus

    n/a
    		 Buy

    Analyst Count

    n/a
    		 4
    Stock Forecasts

    Fair Value

    There are several formulas that can be used to estimate the intrinsic value of a stock.

    Lynch Fair Value

    n/a
    		 n/a

    Lynch Upside

    n/a
    		 n/a

    Graham Number

    n/a
    		 2.22

    Graham Upside

    n/a
    		 -85.6%

    Scores

    Altman Z-Score

    n/a
    		 9.65

    Piotroski F-Score

    n/a
    		 2

    Add to Watchlist